Luminex (LMNX) receives EUA for its ARIES SARS-CoV-2 Assay, which will be used to rapidly detect the virus causing COVID-19.
We've lost count of how many times insiders have accumulated shares in a company that goes on to improve markedly. On...
Hedge funds don't get the respect they used to get. Nowadays investors prefer passive funds over actively managed funds. One thing they don't realize is that 100% of the passive funds didn't see the coronavirus recession coming, but a lot of hedge funds did. Even we published an article near the end of February and […]
Luminex Corporation (NASDAQ: LMNX) ("Luminex") announced today the pricing of its offering of $260,000,000 aggregate principal amount of 3.00% Convertible Senior Notes due 2025 (the "Convertible Notes") in a private placement pursuant to Section 4(a)(2) of the Securities Act of 1933, as amended (the "Securities Act"). The delivery of the Convertible Notes to investors in book-entry form is expected to be made on May 13, 2020, and is expected to result in approximately $218.3 million in net proceeds to Luminex after deducting estimated placement agent's fees, the net cost of the bond hedge and warrant transactions discussed below, and estimated offering expenses payable by Luminex.
Shares in Luminex Corporation (NASDAQ: LMNX) are trading 13.5% lower as of 3:05 p.m. EDT on Friday after the company announced the pricing of its offering of $260 million of 3% convertible senior notes due 2025. The conversion rate on the healthcare company's senior notes is 22.8918 shares of common stock per $1,000 principal amount of convertible notes, which is equivalent to an initial conversion price of $43.68 per share. Luminex is using $34.7 million of the proceeds to pay for its hedges and the remaining money will go to its balance sheet for general use.
Luminex Corporation (Nasdaq: LMNX) (the "Company"), today announced that its board of directors declared a cash dividend for the second quarter of 2020 of $0.09 per share of common stock payable on July 9, 2020 to stockholders of record as of the close of business June 18, 2020.
Despite the widespread coronavirus crisis, there are a few MedTech companies which are expected to have gained in the first quarter.
Zacks.com featured highlights include: Acacia, Virtu and Luminex
Luminex (LMNX) is seeing positive earnings estimate revisions, suggesting that it could be a solid choice for investors.
Luminex (LMNX) has seen solid earnings estimate revision activity over the past month, and belongs to a strong industry as well.
Luminex Corporation (NASDAQ: LMNX) today announced that the Food and Drug Administration (FDA) has issued an Emergency Use Authorization (EUA) for its ARIES® SARS-CoV-2 Assay for rapid detection of the virus that causes COVID-19. The assay runs on the ARIES® System, an FDA-cleared, sample-to-answer, automated, on-demand molecular diagnostic platform. The system is capable of running up to 144 tests per day, requiring no specialty training and minimal human interaction.
With me today is Homi Shamir, our President and CEO. Certain statements made during the course of today's call, may not be purely historical and consequently may be forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, and the Company claims the projections provided by Section 21E of the Securities Exchange Act for such statements.
Luminex Corporation (LMNX) is seeing favorable earnings estimate revision activity and has a positive Zacks Earnings ESP heading into earnings season.
Luminex (LMNX) continues to benefit from robust product portfolio, solid molecular diagnostics and ARIES platforms.
Luminex Corporation today announced 1st quarter 2020 revenues of just over $90 million, up approximately 10% over the 1st quarter of 2019 and approximately 8% above the top end of its previously communicated 1st quarter revenue guidance range of $82 to $84 million. Highlights include:
New Strong Buy Stocks for May 7th
Luminex Corporation (NASDAQ: LMNX) today announced that it has received $642,450 in funding from the Biomedical Advanced Research and Development Authority (BARDA). These funds will help support development, testing, and submission later this week for an Emergency Use Authorization (EUA) for the ARIES® SARS-CoV-2 Assay. This assay will run on the company's sample-to-answer ARIES® System, an FDA-cleared, automated molecular diagnostics platform for moderate complexity labs.
Luminex Corporation (NASDAQ: LMNX) today announced that it plans to report results for the first quarter ended March 31, 2020 on Monday, May 4, 2020. A press release announcing the results is scheduled for release after the close of trading on that date.
Luminex's (LMNX) first-quarter earnings benefit from solid performance across Consumable Sales, Assay, Service and Other Revenues.
Q1 2020 Luminex Corp Earnings Call